FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on preventing cisplatin-induced hearing damage in cancer patients. Its primary commercial product is sodium thiosulfate injection, marketed as PEDMARK in the United States and PEDMARQSI in Europe, the United Kingdom, Australia, and New Zealand. The therapy reduces the risk of ototoxicity in pediatric patients aged one month and older who have localized, non-metastatic solid tumors and are receiving cisplatin chemotherapy. The company's end users are pediatric oncology patients, while its direct customers and distribution partners include hospitals, academic medical centers, community oncology clinics, specialty pharmacies, and international commercial partners.

The company is incorporated under the laws of British Columbia and maintains active subsidiaries in Delaware and Ireland. In the United States, its treatment is supplied to specialized pediatric hospitals and community oncology practices. Internationally, the company commercializes its product through third-party partners across Europe, Australia, New Zealand, Turkey, and Gulf Cooperation Council countries, with commercial availability established in Germany and the United Kingdom.

Summary of the business section of Fennec Pharmaceuticals's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had approximately 35 employees, 19 of whom are in our commercial organization, and the rest of whom are in our G&A organization.”